Triethylene glycol dimethyl ether (TREGDME) dissolving lithium trifluoromethanesulfonate (LiCF3SO3) is studied as a suitable electrolyte medium for lithium battery. Thermal and rheological ...

Editor’s note: This story was updated at 8:47 a.m. June 19, 2025, to note that Merck Manuals – a separate entity from Merck – launched the new tool.

She lauded the Merck Foundation’s Educating Linda initiative, which sponsors underprivileged girls, and in line with her Renewed Hope Initiative that prioritises girl-child education.

Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type ...

Once commercially launched, Merck’s Enflonsia will face stiff competition from AstraZeneca AZN/ Sanofi ’s SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023.

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants. The Food and Drug Administration approved Merck’s preventative drug for ...

The FDA has blessed Merck’s Enflonsia to prevent RSV in infants. The shot will challenge Sanofi and AstraZeneca’s blockbuster Beyfortus.

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 4:15 pm ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

The simplicity of the new monoclonal Enflonsia could give it an advantage over AstraZeneca’s Beyfortus Enflonsia, a monoclonal antibody for RSV, is approved for use in children under 12 months ...